Why do we not yet have combination chemotherapy for chronic hepatitis B?

Joseph J Sasadeusz, Stephen L Locarnini and Graeme Macdonald
Med J Aust 2007; 186 (4): 204-206.
  • Joseph J Sasadeusz1
  • Stephen L Locarnini2
  • Graeme Macdonald3

  • 1 Victorian Infectious Diseases Service, and Centre for Clinical Research Excellence in Infectious Diseases, Royal Melbourne Hospital, Melbourne, VIC.
  • 2 Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC.
  • 3 Princess Alexandra Hospital, and Centre for Diabetes and Endocrine Research, University of Queensland, Brisbane, QLD.


  • 1. Lai C, Ratziu V, Yuen M-F, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-2094.
  • 2. O’Sullivan B, Gidding H, Law M, et al. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health 2004; 28: 212-216.
  • 3. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297.
  • 4. Kucers A. Evolution of antituberculous therapy. In: Kucers A, Crowe S, Grayson M, Hoy J, editors. The use of antibiotics. 5th ed. Oxford: Butterworth-Heinemann, 1997: 1194.
  • 5. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
  • 6. Hammer S, Squires K, Hughes M, et al; AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.
  • 7. Delaney WI, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001; 12: 1-35.
  • 8. Wainberg M, Salomon H, Gu Z, et al. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9: 351-357.
  • 9. Liaw YF, Chien R, Yeh C, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-572.
  • 10. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-693.
  • 11. Liaw Y, Sung J, Chow W, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
  • 12. Chen C, Yang H, Su J, et al. Viral load is a strong predictor of liver cirrhosis risk in people chronically infected with hepatitis B virus regardless of hepatitis B e antigen status. J Hepatol 2005; 42 Suppl 2: 172.
  • 13. Chen G, Lin W, Shen F, et al. Viral load as a predictor of mortality from hepatocellular carcinoma and chronic liver disease in chronic hepatitis B infection. J Hepatol 2005; 42 Suppl 2: 173.
  • 14. Westland C, Yang H, Delaney WE 4th, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67-73.
  • 15. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44: 551-560.
  • 16. Dando T, Plosker G. Adefovir dipivoxil. A review of its use in chronic hepatitis B. Drugs 2003; 63: 2215-2234.
  • 17. Lau G, Piratvisuth T, Luo K, et al; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
  • 18. Marcellin P, Lau G, Bonino F, et al; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
  • 19. Perrillo R, Hann H, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
  • 20. Peters M, Hann HH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 2004; 126: 91-101.
  • 21. Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared with lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis. Abstract 69. J Hepatol 2003; 38 Suppl 2: 25-26.
  • 22. Marcellin P, Chang T, Lim S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.
  • 23. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.
  • 24. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42 Suppl 2: 17.
  • 25. Lampertico P, Marzano A, Levrero M, et al. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 650 patients. 41st Annual Meeting of the European Association for the Study of the Liver; 2006 Apr 26–30; Vienna, Austria. Abstract 116.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.